Cardiff Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRDF and other ETFs, options, and stocks.About CRDF
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
CEOMark Erlander
CEOMark Erlander
Employees33
Employees33
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1999
Founded1999
Employees33
Employees33
CRDF Key Statistics
Market cap162.97M
Market cap162.97M
Price-Earnings ratio-3.01
Price-Earnings ratio-3.01
Dividend yield—
Dividend yield—
Average volume990.21K
Average volume990.21K
High today$2.52
High today$2.52
Low today$2.36
Low today$2.36
Open price$2.49
Open price$2.49
Volume752.89K
Volume752.89K
52 Week high$5.64
52 Week high$5.64
52 Week low$1.90
52 Week low$1.90
Stock Snapshot
With a market cap of 162.97M, Cardiff Oncology(CRDF) trades at $2.36. The stock has a price-to-earnings ratio of -3.01.
On 2025-12-13, Cardiff Oncology(CRDF) stock moved within a range of $2.36 to $2.52. With shares now at $2.36, the stock is trading 0.0% above its intraday low and -6.3% below the session's peak.
Trading volume for Cardiff Oncology(CRDF) stock has reached 752.89K, versus its average volume of 990.21K.
The stock's 52-week range extends from a low of $1.90 to a high of $5.64.
The stock's 52-week range extends from a low of $1.90 to a high of $5.64.
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own CRDF. This list is generated using Robinhood data, and it’s not a recommendation.